Document is current
Any future updates will be listed below
-
Authors
Pauligk, Sophie https://orcid.org/0000-0002-2076-4054
Seidel, Maria
Fürtjes, Sophia
King, Joseph A. https://orcid.org/0000-0002-2864-5578
Geisler, Daniel https://orcid.org/0000-0003-2076-5329
Hellerhoff, Inger https://orcid.org/0000-0002-6152-5834
Roessner, Veit https://orcid.org/0000-0002-1873-7081
Schmidt, Ulrike
Goschke, Thomas
Walter, Henrik https://orcid.org/0000-0002-9403-6121
Strobel, Alexander https://orcid.org/0000-0002-9426-5397
Ehrlich, Stefan https://orcid.org/0000-0003-2132-4445
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EH 367/5-1, SFB 940/2, SFB 940/2, SFB 940/2, SFB 940/2)
B. Braun-Stiftung
- License Information
-
More Information
Article History
Received: 14 July 2020
Revised: 1 April 2021
Accepted: 22 April 2021
First Online: 21 May 2021
Conflict of interest
: V.R. has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire, and Otsuka companies. Funding sources were not involved in the design of the study, the collection and analysis of data, or the decision to publish. The remaining authors declare no competing interests.
